Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Leuk Lymphoma
; 63(13): 3232-3236, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36089918
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Bridged Bicyclo Compounds, Heterocyclic
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Leuk Lymphoma
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United States